Press Release – November 20, 2024 – HAYWARD, Calif. – Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, today announced that Michael A. Klobuchar has been appointed Chief Operating Officer. He joins Eikon from Merck & Co. Inc. where he most recently served as Executive Vice President and Chief Strategy Officer. “Mike is an outstanding leader … Continue reading Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer

Dr. Kleiman brings more than 25 years of neuroscience drug discovery leadership, including the discovery and development of multiple novel clinical candidates Press Releae – October 31, 2024 – MEDFORD, Mass. – Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unmet need central nervous system (CNS) conditions, announces the appointment of Robin Kleiman, Ph.D., as … Continue reading Myrobalan Therapeutics Appoints Robin Kleiman Ph.D., as Chief Scientific Officer